This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Erratum - p. xiii 8. Preface - p. xv 9. Where Does Morphology Fit in Myelodysplastic Syndrome Diagnosis in the Era of Molecular Testing? - p. 321 10. Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice - p. 333 11. The Clinical Management of Clonal Hematopoiesis: Creation of a Clonal Hematopoiesis Clinic - p. 357 12. Novel Prognostic Models for Myelodysplastic Syndromes - p. 369 13. Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity - p. 379 14. Luspatercept in Myelodysplastic Syndromes: Who and When? - p. 393 15. Treatment of Acquired Sideroblastic Anemias - p. 401 16. Targeting TP53 Mutations in Myelodysplastic Syndromes - p. 421 17. Prospects for Venetoclax in Myelodysplastic Syndromes - p. 441 18. Secondary Acute Myeloid Leukemia: A Primary Challenge of Diagnosis and Treatment - p. 449 19. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation? - p. 465 20. Assessing Symptom Burden in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Patients - p. 475
No hay muestra disponible
No hay ficha técnica disponible
This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Erratum - p. xiii 8. Preface - p. xv 9. Where Does Morphology Fit in Myelodysplastic Syndrome Diagnosis in the Era of Molecular Testing? - p. 321 10. Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice - p. 333 11. The Clinical Management of Clonal Hematopoiesis: Creation of a Clonal Hematopoiesis Clinic - p. 357 12. Novel Prognostic Models for Myelodysplastic Syndromes - p. 369 13. Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity - p. 379 14. Luspatercept in Myelodysplastic Syndromes: Who and When? - p. 393 15. Treatment of Acquired Sideroblastic Anemias - p. 401 16. Targeting TP53 Mutations in Myelodysplastic Syndromes - p. 421 17. Prospects for Venetoclax in Myelodysplastic Syndromes - p. 441 18. Secondary Acute Myeloid Leukemia: A Primary Challenge of Diagnosis and Treatment - p. 449 19. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation? - p. 465 20. Assessing Symptom Burden in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Patients - p. 475
No hay muestra disponible
No hay ficha técnica disponible
